Novo Nordisk Annual Report 2021
Contents
Introducing Novo Nordisk
Strategic Aspirations
Key risks
Management
Consolidated statements
Additional information.
Novo Nordisk Annual Report 2021 14
the use of renewable power was recognised during Climate
Week New York City in September 2021, when Novo Nordisk
was awarded the RE100 Key Collaborator Award for its work in
accelerating the global transition to 100% renewable energy.
Stepping up to the plastic challenge
Cutting CO₂ emissions is only a part of our ambitious goal of
creating a business with zero environmental impact. We also
recognise the need to minimise the use of fossil-based plastic,
which is one of our major challenges, as we produce more than
600 million pre-filled pens every year, which are an essential daily
companion for people living with diabetes. We must find good
solutions to minimise the use of fossil-based plastic by innovating
new products, shifting to more sustainable material and
establishing recycling opportunities for our pre-filled pens globally.
We use more than 12,000 tonnes of plastic every year in the
production of our devices. As medical waste, they are difficult to
recycle. However, a pioneering take-back initiative piloted over the
past year in Denmark shows that it is possible to reclaim and reuse
the plastic that makes up three-quarters of these devices. Material
from scrapped insulin pens has already been successfully used for
the manufacture of lamps and office furniture. Over the next three
years, we also aim to roll out pen recycling pilots in other markets,
starting with the UK, France and Brazil.
Further out, we are investigating the potential to develop non
fossil fuel-derived plastics by harnessing waste carbon and
hydrogen from energy supply processes, including through the
use of carbon capture.
Please refer to the Sustainability Standards section on pages
22 and 23 for more information on our reporting in the
environmental dimension.
What are Scope 1, 2 & 3 emissions?
A company's greenhouse gas emissions can be classified into three scopes. These scopes are
defined with reference to how directly a company influences the emissions - with Scope 3 being
the hardest to monitor and address. Novo Nordisk's reporting of Scope 3 emissions is currently
limited to product distribution and business flights. This means that the data shown below do not
include a significant proportion of the Scope 3 emissions from our value chain.
Scope 1
Direct emissions from company-
owned and controlled resources
(including emissions from production
processes and transport)
Scope 2
Indirect emissions from the
generation of energy purchased from
a utility provider (including electricity,
steam, heat and cooling)
77,000
tonnes of CO₂
16,000
tonnes of CO₂
Total CO₂ emissions from operations and transportation
Scope 3
All indirect emissions - not included
in Scope 2- that occur in the value
chain of the reporting company
(including both upstream and
downstream emissions)
Novo Nordisk's reporting of
Scope 3 emissions is currently
limited to product distribution
and business flights
81,000
tonnes of CO₂
174,000 tonnesView entire presentation